Generic competition and market exclusivity periods in pharmaceuticals

Managerial and Decision Economics

Volumn 28, Issue 4-5, 2007, Pages 491-502

  Grabowski, Henry G ^a   Kyle, Margaret ^b  

^a DUKE UNIVERSITY   (United States)

^b LONDON BUSINESS SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548359290     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.1356     Document Type: Article

References (15)

1. DiMasi J, Hansen R, Grabowski H. 2003. 'The price of innovation: new estimates of drug development costs.' Journal of Health Economics 22: 141-185.
2. DiMasi J, Grabowski H, Vernon J. 2004. 'R&D Costs and returns by therapeutic category.' Drug Information Journal 38(3): 211-223.
3. Grabowski H, Vernon J. 1992. 'Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 act.' Journal of Law and Economics 35(2): 331-350.
4. Grabowski H. Vernon J. 1994. 'Returns to R&D on new drug introductions in the 1980s.' Journal of Health Economics 13: 383-406.
5. Grabowski H, Vernon J. 2000. 'The distribution of sales revenues from pharmaceutical innovation.' PharmacoEconomics 18(suppl. 1): 21-32.
6. Grabowski H, Vernon J, DiMasi J. 2002. 'Returns on research and development for the 1990s new drug introductions. PharmcoEconomics 20(suppl. 3): 11-29.
7. Grabowski H. 2004. 'Are the economics of pharmaceutical R&D changing: productivity, patents, and political pressures.' PharmacoEconomics 22(Suppl. 2): 15-24.
8. HHS News, May 5, 1997. 'FDA Statement on Generic Premarin,: (www.fda.gov/bbs/topics/NEWS/NEW00565. html)
9. Johnson Jr AC, Johnson MB, Buse RC. 1987. Econometrics Basic and Applied. MacMillan: New York.
10. Mossinghoff GJ. 1999. 'Overview of the Hatch-Waxman Act and its impact on the drug development process.' Food Drug and Law Journal 54(2): 194-197.
11. NIHCM Foundation. 2000. 'Prescription Drugs and Intellectual Property Protection.' NIHCM: Washington, DC, August.
12. Padden M, Jenkins T. 2004, 'Hatch-Waxman changes.' The National Law Journal 26(25): 2. February 23. http://www.howrey.com/docs/ 00503040006Howrey.pdf
13. Reiffen D, Ward M. 2002. 'Generic drug industry dynamics.' Federal Trade Commission Working Paper.
14. Scott-Morton FM. 1999. 'Entry decisions in the generic pharmaceutical industry.' RAND Journal of Economics 30(3): 421-440.
15. US Congressional Budget Office. 1998. 'How Increased Competition Has Affected Prices and Returns in the Pharmaceutical Industry.' Washington, DC; 38.